Skip to Content

Join the 'Upper Limb Spasticity' group to help and get support from people like you.

Upper Limb Spasticity News

Specially Designed Video Game Might Ease 'Phantom Limb' Pain

Posted 7 days ago by Drugs.com

THURSDAY, Dec. 1, 2016 – Amputees who experience what is known as phantom limb pain may benefit from playing a virtual reality game that simulates the movement of missing limbs, a small study suggests. "Phantom limb pain is a difficult condition to treat that can seriously hinder patients' quality of life," said study lead author Max Ortiz Catalan. He is an assistant professor at Sweden's Chalmers University of Technology. Phantom limb pain occurs when amputees feel painful sensations that appear to be coming from limbs that no longer exist. In about one-third of cases, the pain can lead to poor mental health and worsening disability, the study authors noted. "The results from our study suggest that it may be useful to 'exercise' the phantom limb," Catalan explained. "Our treatment offers an engaging way to do this while also providing a non-invasive and non-pharmacological treatment, ... Read more

Related support groups: Neuropathic Pain, Periodic Limb Movement Disorder, Spinal Cord Trauma, Autonomic Neuropathy, Central Nervous System Disorders, Upper Limb Spasticity, Lower Limb Spasticity

Could Low Vitamin D Levels at Birth Mean Higher MS Risk?

Posted 8 days ago by Drugs.com

THURSDAY, Dec. 1, 2016 – Newborns with low levels of vitamin D may have higher odds of developing multiple sclerosis (MS) later in life, new research suggests. Vitamin D deficiency is common among the general population, including pregnant women. But the researchers said it's too soon to routinely recommend "sunshine vitamin" supplements for mothers-to-be. "The study does not prove that increasing vitamin D levels reduces the risk of MS. Further studies are needed to confirm our results," said study leader Dr. Nete Munk Nielsen, a researcher at the Statens Serum Institute in Copenhagen, Denmark. About 2.5 million people worldwide have MS. It's a chronic disease of the central nervous system characterized by damage to myelin, the fatty substance coating nerve fibers. MS symptoms vary, but can include walking difficulties, fatigue, numbness and vision problems. A growing body of evidence ... Read more

Related support groups: Multiple Sclerosis, Vitamin D Deficiency, Vitamin/Mineral Supplementation and Deficiency, Delivery, Vitamin/Mineral Supplementation during Pregnancy/Lactation, Chronic Spasticity, Caltrate 600 with D, Vitamin D Insufficiency, Spasticity, Upper Limb Spasticity, Citracal + D, Calcium/Vitamin D, Oysco 500 with D, Citracal Petites, Lower Limb Spasticity, Spinal Spasticity, Citracal Creamy Bites, Oyster Shell Calcium, Calcet, Prematurity/Underweight in Infancy

MS Symptoms May Develop Earlier in Darker, Cooler Climes

Posted 4 Nov 2016 by Drugs.com

THURSDAY, Nov. 3, 2016 – The farther from the Equator someone with multiple sclerosis lives, the earlier symptoms begin, a new study finds. MS is a progressive disease affecting the central nervous system. Although symptoms vary, they often include fatigue, dizziness, weakness, numbness or tingling, trouble walking and vision problems. The cause of MS is thought to be an interplay of genetic and environmental factors, including latitude and/or exposure to sunlight and vitamin D levels. But it wasn't known if latitude – the distance north or south of the Equator – affected the age when symptoms start. To examine the issue, Dr. Bruce Taylor, a professor at Menzies Institute for Medical Research at the University of Tasmania, and colleagues analyzed data from more than 22,000 MS patients in Australia and 20 countries in Europe, North and South America and Asia. According to the new ... Read more

Related support groups: Multiple Sclerosis, Chronic Spasticity, Spasticity, Upper Limb Spasticity, Spinal Spasticity, Lower Limb Spasticity

Powerful MS Drug Used Early May Reverse Some Disability

Posted 14 Oct 2016 by Drugs.com

FRIDAY, Oct. 14, 2016 – A multiple sclerosis drug usually reserved for people in the late stages of the disease seems to offer long-term remission in newly diagnosed patients, researchers report. Because of serious side effects, the drug – Lemtrada (alemtuzumab) – is approved in the United States only for patients who have failed other treatments. But the authors of a new study believe giving it early may slow and even reverse some disease-related disability. "The expectation in MS has always been to try to slow down the progression of the disease. Now we can tell our patients that a significant number can actually improve by reversing their disability," said lead researcher Dr. Gavin Giovannoni. He is a neurology professor at Queen Mary University of London in England. The treatment is not without its downsides, however. Because of the potential for side effects, people who received ... Read more

Related support groups: Multiple Sclerosis, Chronic Spasticity, Spasticity, Upper Limb Spasticity, Lemtrada, Campath, Lower Limb Spasticity, Alemtuzumab, Spinal Spasticity

Drug Shows Promise Against MS in Mouse Study

Posted 22 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 21, 2016 – An experimental drug, laquinimod, appears to prevent or slow the progression of multiple sclerosis (MS) in mice, according to a new study. "This study has given us more insight into how laquinimod works," said study author Dr. Scott Zamvil, of the University of California, San Francisco. "But because this was an animal study, more research needs to be done before we know if it could have similar results in people." Still, "these results are promising because they provide hope for people with progressive MS, an advanced version of the disease for which there is currently no treatment," Zamvil said in a news release from the American Academy of Neurology. A healthy immune system has T cells and B cells that help the body prevent infections. However, for people with MS, these cells create antibodies that attack and destroy the protective outer coating (myelin) ... Read more

Related support groups: Multiple Sclerosis, Chronic Spasticity, Spasticity, Diagnosis and Investigation, Upper Limb Spasticity, Lower Limb Spasticity, Spinal Spasticity

Treating Early Symptoms of MS May Extend Time to Diagnosis

Posted 11 Aug 2016 by Drugs.com

THURSDAY, Aug. 11, 2016 – Starting multiple sclerosis (MS) treatment when the first signs of the disabling disease appear may delay the period before the condition is definitively diagnosed or a relapse occurs, new long-term research indicates. Researchers found that people who received early treatment for symptoms consistent with the onset of MS were one-third less likely to eventually be diagnosed with MS than participants whose treatment was delayed. Those symptoms include numbness, or vision or balance problems. Patients in the early treatment group also experienced a 19 percent lower annual relapse rate, the study found. "The surprise is that after 11 years, we were still able to detect a difference favoring early treatment, although the delay in starting treatment in the delayed treatment group was only 1.5 years on average," said study author Dr. Ludwig Kappos. He's a professor ... Read more

Related support groups: Multiple Sclerosis, Chronic Spasticity, Betaseron, Spasticity, Upper Limb Spasticity, Lower Limb Spasticity, Spinal Spasticity

MS Stem Cell Therapy Succeeds But Poses Risks

Posted 10 Jun 2016 by Drugs.com

THURSDAY, June 9, 2016 – A treatment combining chemotherapy and a stem cell transplant could represent a major advance against aggressive multiple sclerosis, experts say. This new treatment destroys the immune system with chemo and rebuilds it with the patient's own stem cells. Researchers say it stopped MS relapses and progression in 23 of 24 patients. According to the results of this small trial, these 23 patients no longer needed medication to control their MS. Moreover, eight showed continued improvement for nearly eight years. "These patients had highly active MS with lots of relapses and lots of ongoing damage to their brain, but we've been able to stop that," said lead researcher Dr. Harold Atkins. He is an associate professor of clinical hematology at the University of Ottawa in Canada. The results are noteworthy, Atkins said. "There are lots of drugs and treatments available ... Read more

Related support groups: Multiple Sclerosis, Chronic Spasticity, Spasticity, Diagnosis and Investigation, Upper Limb Spasticity, Lower Limb Spasticity, Spinal Spasticity

Botox Can Be Used for Chronic Migraine, Experts Say

Posted 18 Apr 2016 by Drugs.com

MONDAY, April 18, 2016 – Botox is a safe and effective treatment for chronic migraine and three other neurological disorders, an updated guideline from the American Academy of Neurology says. Long used to smooth wrinkles, botulinum toxin is made by a type of bacteria. The toxin blocks the release of substances at nerve endings, reducing muscle contraction and the transmission of pain signals, the researchers explained. The authors of the updated guideline reviewed scientific studies on the four preparations of botulinum toxin available in the United States. They concluded that the treatment is generally safe and effective for four neurological conditions: chronic migraine, spasticity in adults, cervical dystonia and blepharospasm. Chronic migraine is defined as having migraines 15 or more days a month, the study authors explained. Spasticity in adults is muscle tightness that ... Read more

Related support groups: Migraine, Migraine Prevention, Migraine Prophylaxis, Facial Wrinkles, Cervical Dystonia, Chronic Spasticity, Blepharospasm, Spasticity, Upper Limb Spasticity, Spinal Spasticity, Lower Limb Spasticity, Botulinum Toxin Type B, Myobloc

Heavy Coffee Drinkers Show Lower Risk of Multiple Sclerosis

Posted 4 Mar 2016 by Drugs.com

THURSDAY, March 3, 2016 – People who drink a lot of coffee may have a lower risk of developing multiple sclerosis (MS), a new large study suggests. Researchers found that among more than 6,700 adults, those who downed about six cups of coffee a day were almost one-third less likely to develop MS than non-drinkers were. And the link was not explained away by factors such as people's age, education or income levels, or smoking and drinking habits. Still, experts stressed that the findings do not prove that coffee, or big doses of caffeine, fight MS. Nor is anyone suggesting that people drink more java to ward off the disease, said lead researcher Anna Hedstrom, of the Karolinska Institute in Stockholm, Sweden. She said the findings do add to evidence that coffee "may have beneficial effects on our health" – but there is no way to make any specific recommendations. Elaine Kingwell, a ... Read more

Related support groups: Multiple Sclerosis, Caffeine, Fioricet, Excedrin, Alert, Fiorinal, Excedrin Migraine, Cafergot, Chronic Spasticity, Fiorinal with Codeine, Norgesic, Esgic, Headache Relief, Fioricet with Codeine, Keep Going, Esgic-Plus, Acetaminophen/Butalbital/Caffeine, Excedrin Extra Strength, Stay Awake, Norgesic Forte

MS Drug Tied to Higher Risk for Potentially Deadly Brain Virus

Posted 28 Jan 2016 by Drugs.com

WEDNESDAY, Jan. 27, 2016 – People with multiple sclerosis who are treated with the drug Tysabri (natalizumab) may have up to a 10 times greater risk for a rare and potentially deadly viral infection, a new study finds. The germ in question is the John Cunningham virus (JCV), a pathogen thought to cause a deadly brain condition known as progressive multifocal leukoencephalopathy (PML). The link between Tysabri and PML isn't new: Numerous studies published over the past few years have shown an increase in risk for the disease in patients taking the drug. However, even though the new study showed a link between Tysabri and JCV infection, experts stressed that the drug can be of great help to patients, who should weigh its benefits against its risks. The new research was led by Dr. Heinz Wiendl of the University of Muenster in Germany. The findings are published in the Jan. 27 online ... Read more

Related support groups: Multiple Sclerosis, Tysabri, Chronic Spasticity, Viral Infection, Upper Limb Spasticity, Natalizumab, Lower Limb Spasticity

Could High-Dose Vitamin D Help Fight Multiple Sclerosis?

Posted 31 Dec 2015 by Drugs.com

WEDNESDAY, Dec. 30, 2015 – High-dose vitamin D appears safe for people with multiple sclerosis, and it may help quiet the immune system hyperactivity that marks the disease, a small clinical trial finds. The study, published online Dec. 30 in Neurology, bolsters evidence that vitamin D might benefit people with MS. But clinical trials are still underway to answer the big question: Does taking vitamin D improve MS symptoms and alter the course of the disease? The current study shows only that high doses – 10,400 IU a day – reduce the proportion of certain immune-system cells that have been implicated in the MS disease process. "I'm not going to make any claims beyond that," said senior researcher Dr. Peter Calabresi, a professor of neurology at Johns Hopkins University in Baltimore. "We don't have enough data here to guide clinical practice," he stressed. Bruce Bebo, executive vice ... Read more

Related support groups: Multiple Sclerosis, Dietary Supplementation, Vitamin D Deficiency, Vitamin/Mineral Supplementation and Deficiency, Chronic Spasticity, Caltrate 600 with D, Vitamin D Insufficiency, Calcium/Vitamin D, Citracal + D, Upper Limb Spasticity, Os-Cal 500 with D, Rickets, Oysco 500 with D, Citracal Petites, Calcium 600 D, Citracal Creamy Bites, Calcet, Oyster Shell Calcium, Calcarb with D, Osteocit D Plus

Merz North America Announces FDA Approval of Xeomin (incobotulinumtoxinA) for Treatment of Adult Upper Limb Spasticity

Posted 30 Dec 2015 by Drugs.com

RALEIGH, N.C.- December 23, 2015 --Merz North America, U.S. affiliate of the global Merz Pharma Group, announces that Xeomin (incobotulinumtoxinA) has received U.S. FDA approval for the treatment of upper limb spasticity (ULS) in adult patients. In clinical studies, treatment with Xeomin (incobotulinumtoxinA) for adult ULS resulted in statistically and clinically significant improvements in muscle tone, with a safety profile similar to that observed for other Xeomin (incobotulinumtoxinA) indications. “We know that each patient has unique needs, and this new indication for Xeomin (incobotulinumtoxinA) is a result of our long-term commitment to serving individuals living with movement disorders and spasticity,“ said Glenn Block, Vice President and Head – US Neurosciences for Merz North America. “We look forward to supporting the launch of Xeomin for adult upper-limb spasticity with forwar ... Read more

Related support groups: Upper Limb Spasticity, Xeomin, Incobotulinumtoxina

New MS Drug Yields Mixed Results in Study

Posted 7 Oct 2015 by Drugs.com

WEDNESDAY, Oct. 7, 2015 – Multiple sclerosis patients taking a new drug experienced fewer relapse rates but more side effects than patients receiving a standard MS therapy, new research indicates. In a trial comparing two sets of more than 900 patients with relapsing-remitting multiple sclerosis, scientists found that those taking the drug daclizumab HYP had a 45 percent lower relapse rate than those taking interferon beta-1a. But patients on the new drug, which has not yet been approved by the U.S. Food and Drug Administration, saw more side effects. Also, they did not experience significantly slower disease progression than those in the interferon beta-1a group over the first several months. "This is one more drug for multiple sclerosis, which is of course very welcome, but it's just one in addition to the 11 or 12 drugs we already have," said Dr. Eugene Lai, a neurologist at Houston ... Read more

Related support groups: Multiple Sclerosis, Avonex, Rebif, Chronic Spasticity, Upper Limb Spasticity, Interferon Beta-1A, Avonex Prefilled Syringe, Daclizumab, Rebif Rebidose, Zenapax, Avonex Pen

Ipsen Announces FDA Approval of Dysport (abobotulinumtoxinA) for Upper Limb Spasticity

Posted 24 Jul 2015 by Drugs.com

Paris (France), 16 July 2015 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for Dysport (abobotulinumtoxinA) for the treatment of upper limb spasticity in adult patients after the submission of the dossier in September 2014. Dysport is now approved for the treatment of upper limb spasticity in adult patients, to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors. Clinical improvement may be expected one week after administration of Dysport. A majority of patients in clinical studies were retreated between 12 and 16 weeks; some patients had a duration of response as long as 20 weeks. In Europe, regulatory procedures are in progress for strengthening the existing upper limb spasticity label indication of Dysport to i ... Read more

Related support groups: Dysport, Upper Limb Spasticity, Abobotulinumtoxina

Ask a Question

Further Information

Related Condition Support Groups

Spasticity

Related Drug Support Groups

Botox, Dysport, onabotulinumtoxina, Xeomin, incobotulinumtoxina, abobotulinumtoxina